NCT02221882View on ClinicalTrials.gov

A Study of LY3164530 in Participants With Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

March 7, 2017

Study Completion Date

March 7, 2017

Conditions
NeoplasmsNeoplasm Metastasis
Interventions
DRUG

LY3164530

Administered IV.

Trial Locations (3)

77030

University of Texas MD Anderson Cancer Center, Houston

78229

The START Center for Cancer Care, San Antonio

85258

Pinnacle Oncology Hematology, Scottsdale

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT02221882 - A Study of LY3164530 in Participants With Cancer | Biotech Hunter | Biotech Hunter